Tags

Type your tag names separated by a space and hit enter

A personal experience with pancreatic and duodenal neuroendocrine tumors.
J Am Coll Surg. 1999 Nov; 189(5):470-82.JA

Abstract

BACKGROUND

Since the concept of hormones was proposed in 1901, numerous gastrointestinal hormones and neuroendocrine tumors that can produce these hormones have been identified. The most common tumors are gastrinomas and insulinomas.

STUDY DESIGN

During a 35-year experience, there were 82 neuroendocrine tumors, including 37 gastrinomas, 11 insulinomas, 16 nonfunctioning tumors, 11 gastrinomas suspected but not found, 3 tumors arising in lymph nodes, 1 somatostatinoma, 1 glucagonoma, and 2 amphicrine tumors. MEN I syndrome coexisted with three pancreatic gastrinomas, two pancreatic and duodenal gastrinomas, four suspected gastrinomas, one nonfunctioning tumor, two insulinomas, and no duodenal gastrinomas.

RESULTS

Of the nine patients with pancreatic gastrinoma without MEN I, three had lymph node, three had liver metastases, and one had both. The mean survival time was 4.8 years. Three patients with pancreatic gastrinoma and MEN I were alive at 2, 17, and 20 years, respectively. Of the 20 patients with duodenal gastrinoma, none had MEN I; 13 had lymph node metastases and 1 had liver metastases. The overall followup was 7.0 years. Ten patients were biochemically cured. Nonfunctioning tumors, with one exception, originated in the pancreas. Of the three gastrinomas potentially arising in lymph nodes, two, and possibly three, were cured by node removal. Eleven patients had an insulinoma. No patient had recurrence of hypoglycemia after removal of an insulinoma.

CONCLUSIONS

Patients with duodenal gastrinoma with lymph node metastases were curable, and cures were achieved occasionally after resection of liver metastases. Results of operation were similar for those with and without MEN I. MEN I and metastases were not contraindications to operation; instead, these patients should be operated on aggressively. Gastrinomas not found at operation were likely to be small duodenal gastrinomas. Gastrinomas can arise in a lymph node and can be cured by its removal. Parietal cell vagotomy is recommended after operation for gastrinomas in the event of residual tumor. With the exception of patients with MEN I or microadenomata, insulinomas were treated best by tumor enucleation. Otherwise, Whipple operation or distal pancreatectomy and enucleation of tumor in the remaining pancreas was indicated.

Authors+Show Affiliations

Department of Surgery, Baylor College of Medicine, The Veteran's Adaministration Medical Center, The Methodist Hospital, Houston, TX, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10549736

Citation

Jordan, P H.. "A Personal Experience With Pancreatic and Duodenal Neuroendocrine Tumors." Journal of the American College of Surgeons, vol. 189, no. 5, 1999, pp. 470-82.
Jordan PH. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg. 1999;189(5):470-82.
Jordan, P. H. (1999). A personal experience with pancreatic and duodenal neuroendocrine tumors. Journal of the American College of Surgeons, 189(5), 470-82.
Jordan PH. A Personal Experience With Pancreatic and Duodenal Neuroendocrine Tumors. J Am Coll Surg. 1999;189(5):470-82. PubMed PMID: 10549736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A personal experience with pancreatic and duodenal neuroendocrine tumors. A1 - Jordan,P H,Jr PY - 1999/11/5/pubmed PY - 2001/3/28/medline PY - 1999/11/5/entrez SP - 470 EP - 82 JF - Journal of the American College of Surgeons JO - J Am Coll Surg VL - 189 IS - 5 N2 - BACKGROUND: Since the concept of hormones was proposed in 1901, numerous gastrointestinal hormones and neuroendocrine tumors that can produce these hormones have been identified. The most common tumors are gastrinomas and insulinomas. STUDY DESIGN: During a 35-year experience, there were 82 neuroendocrine tumors, including 37 gastrinomas, 11 insulinomas, 16 nonfunctioning tumors, 11 gastrinomas suspected but not found, 3 tumors arising in lymph nodes, 1 somatostatinoma, 1 glucagonoma, and 2 amphicrine tumors. MEN I syndrome coexisted with three pancreatic gastrinomas, two pancreatic and duodenal gastrinomas, four suspected gastrinomas, one nonfunctioning tumor, two insulinomas, and no duodenal gastrinomas. RESULTS: Of the nine patients with pancreatic gastrinoma without MEN I, three had lymph node, three had liver metastases, and one had both. The mean survival time was 4.8 years. Three patients with pancreatic gastrinoma and MEN I were alive at 2, 17, and 20 years, respectively. Of the 20 patients with duodenal gastrinoma, none had MEN I; 13 had lymph node metastases and 1 had liver metastases. The overall followup was 7.0 years. Ten patients were biochemically cured. Nonfunctioning tumors, with one exception, originated in the pancreas. Of the three gastrinomas potentially arising in lymph nodes, two, and possibly three, were cured by node removal. Eleven patients had an insulinoma. No patient had recurrence of hypoglycemia after removal of an insulinoma. CONCLUSIONS: Patients with duodenal gastrinoma with lymph node metastases were curable, and cures were achieved occasionally after resection of liver metastases. Results of operation were similar for those with and without MEN I. MEN I and metastases were not contraindications to operation; instead, these patients should be operated on aggressively. Gastrinomas not found at operation were likely to be small duodenal gastrinomas. Gastrinomas can arise in a lymph node and can be cured by its removal. Parietal cell vagotomy is recommended after operation for gastrinomas in the event of residual tumor. With the exception of patients with MEN I or microadenomata, insulinomas were treated best by tumor enucleation. Otherwise, Whipple operation or distal pancreatectomy and enucleation of tumor in the remaining pancreas was indicated. SN - 1072-7515 UR - https://www.unboundmedicine.com/medline/citation/10549736/A_personal_experience_with_pancreatic_and_duodenal_neuroendocrine_tumors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1072-7515(99)00162-3 DB - PRIME DP - Unbound Medicine ER -